A Miami-based health technology company just got a big boost in its mission to support cancer patients.
Carevive Systems announced its received an $18 million Series C equity investment, led by Philips Health Technology Ventures and supported by Debiopharm Innovation Fund, Qure Ventures (OurCrowd’s digital health fund), LRVHealth, Cerner and HLM Venture Partners. The investment round was oversubscribed, demonstrating the investors’ excitement.
“We have been following Carevive’s development for some time,” said Allen Kamer, managing partner at Qure Ventures, in a release. “Carevive made significant progress in the last year, is now in dozens of hospitals around the US and was selected by Pfizer as the first Patient-Reported Outcomes (PRO) challenge winner for Carevive PROmpt. We are excited by the company’s growth and the addition of Bruno, a veteran of the health and data analytics industry, to Carevive’s senior leadership team.”
Carevive CEO Bruno Lempernesse said the funds will bring the company’s software and analytics platform to more patients and clinicians. The platform “connects clinical data with patients’ real-world reported experiences,” allowed care to be based on more than data. The company says patients require fewer health center visits thanks to its remote symptom management system.
“I’m delighted to be starting off my tenure with an announcement like this,” said Lempernesse, who was appointed CEO in December. “This financing will advance Carevive’s patient-centered mission to improve the way cancer care is delivered. I’m proud to be leading such an innovative company with committed industry-leading investors supporting us.”
Carevive says it will continue investing in data analytics, infrastructure and technology while focusing on remote patient management functionality, patient experience studies and growing its Oncology Pragmatic Trial Investigator Network.
